• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Namenda (memantine hydrochloride) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

October 2013

Summary View

ADVERSE DRUG REACTIONS

Postmarketing Experience
  • Blood and Lymphatic System Disorders - agranulocytosis, pancytopenia, thrombotic thrombocytopenic purpura.